Table 2.

Comparison of the carbamazepine, gabapentin or pregabalin efficacy on neonatal mother-separated and dextran sulfate sodium induced colonic hypersensitivity models

		NMS	DSS
CBZ	10 mg/kg	9 ± 8	6 ± 18
	30 mg/kg	5 ± 13	-17 ± 15
GBP	30 mg/kg	15 ± 32	-45 ± 9
	100 mg/kg	-14 ± 37	-56 ± 9
PGB	10 mg/kg	-16 ± 8	-54 ± 7a
	30 mg/kg	-47 ± 13	-66 ± 7b

On the same mouse, the visceromotor response to gradual colorectal distensions (CRD) has been evaluated before and after the first and the second injection of CBZ, GBP or PGB. For each gradual CRD, the area under the curve (AUC) has been calculated between 80 μL and 100 μL in NMS model or between 60 μL and 80 μL for DSS model. Data represented the mean percent variation of the AUC calculated after the first or the second injection in comparison to the AUC calculated before any injection.

^aP < 0.05,

^bP < 0.01 NMS I DSS treated ANOVA 1 Way followed by Tuckey’s post-hoc test for multiple comparisons. CBZ: Carbamazepine; GBP: Gabapentin; PGB: Pregabalin; NMS: Neonatal maternal separation; DSS: Dextran sulfate sodium.